KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Invested Capital: 2011-2025

Historic Invested Capital for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $1.1 billion.

  • Supernus Pharmaceuticals' Invested Capital rose 0.68% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 0.68%. This contributed to the annual value of $1.1 billion for FY2024, which is 11.25% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Invested Capital stood at $1.1 billion for Q3 2025, which was down 0.28% from $1.1 billion recorded in Q2 2025.
  • Supernus Pharmaceuticals' Invested Capital's 5-year high stood at $1.3 billion during Q3 2022, with a 5-year trough of $786.0 million in Q1 2021.
  • Its 3-year average for Invested Capital is $1.0 billion, with a median of $1.0 billion in 2024.
  • In the last 5 years, Supernus Pharmaceuticals' Invested Capital surged by 54.06% in 2021 and then dropped by 24.29% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Invested Capital (MRQ) stood at $1.2 billion in 2021, then decreased by 24.08% to $907.3 million in 2022, then increased by 7.30% to $973.6 million in 2023, then increased by 11.25% to $1.1 billion in 2024, then dropped by 2.05% to $1.1 billion in 2025.
  • Its Invested Capital was $1.1 billion in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.1 billion in Q1 2025.